Close Menu

IBM

The researchers developed a plasma protein signature that can identify patients with cerebrospinal fluid amyloid-β42 levels indicative of risk for the disease.

To combat the challenge of counterfeit diagnostic tests, IBM scientists have developed a method to embed security codes to authenticate diagnostic tests.

The Martinos Center, Envision Genomics, and startup RowAnalytics are building an open precision medicine platform called Giro Health on IBM architecture.